

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/N3FFA60BCEF0EN.html>

Date: November 2022

Pages: 67

Price: US\$ 3,500.00 (Single User License)

ID: N3FFA60BCEF0EN

Abstracts

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report GMDHC22228TDB, outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Neuronal acetylcholine receptor subunit alpha-7 is a protein encoded by the CHRNA7 gene. After binding to acetylcholine it undergoes an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 3 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Immunology and Oncology which include indications Alzheimer's Disease, Traumatic Brain Injury, Anxiety Disorders, Cognitive Impairment, Pain,

Parkinson's Disease, Schizophrenia, Bipolar Disorder (Manic Depression), Cognitive Disorders, Cognitive Impairment Associated With Schizophrenia (CIAS), Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), Dementia Associated With Alzheimer's Disease, Inflammation, Ischemic Stroke, Major Depressive Disorder, Mild Cognitive Impairment, Neuropathic Pain (Neuralgia), Panic Disorders, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD/Social Phobia), Ulcerative Colitis and Unspecified Pain.

Furthermore, this report also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7)

The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics and enlists all their major and minor projects

The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Overview

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Companies Involved in
Therapeutics Development

180 Life Sciences Corp

AlphaCognition Inc

AstraZeneca Plc

Bionomics Ltd

Bristol-Myers Squibb Co

DanPET AB

Epigen Biosciences Inc

Lupin Ltd

Merck & Co Inc

Neuro Bio Ltd

Serenity Bioworks Inc

SK Life Science Inc

Vanda Pharmaceuticals Inc

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Drug Profiles

a7nAChR - Drug Profile

Product Description

Mechanism Of Action

History of Events

ALPHA-1062 - Drug Profile

Product Description

Mechanism Of Action
History of Events
AVL-8168 - Drug Profile
Product Description
Mechanism Of Action
AZD-0328 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BMS-910731 - Drug Profile
Product Description
Mechanism Of Action
BNC-210 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BNC-375 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EPGN-1137 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LL-00066471 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NBP-14 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NS-12877 - Drug Profile
Product Description
Mechanism Of Action
SER-400 - Drug Profile
Product Description
Mechanism Of Action
SKL-20540 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Agonize CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

VQW-765 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Dormant Products

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Discontinued Products

Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) - Product Development Milestones

Featured News & Press Releases

Sep 21, 2022: Bionomics to host KOL webinar on BNC210 and social anxiety disorder

Aug 23, 2022: Alpha Cognition reports positive data from Alzheimer's therapy study

Jun 22, 2022: Alpha Cognition announces positive results from pivotal study with ALPHA-1062 in development for Alzheimer's Disease

May 10, 2022: Novamind to host Bionomics PREVAIL trial for acute treatment of social anxiety disorder

Apr 06, 2022: Novel Drug from Neuro-Bio effective in a mouse model of Alzheimer's Disease

Feb 22, 2022: Alpha Cognition announces positive neuroprotection data from pre-clinical study of ALPHA-1062 for Traumatic Brain Injury

Jan 03, 2022: Bionomics initiates phase 2 PREVAIL study of BNC210 for the acute treatment of social anxiety disorder

Dec 06, 2021: Alpha Cognition announce data from pre-clinical study of ALPHA-1062 for traumatic brain injury

Dec 01, 2021: U.S. FDA grants Bionomics Fast Track Designation to BNC210 for the acute treatment of social anxiety disorder and other anxiety related disorders

Nov 01, 2021: Bionomics Receives FDA clearance of IND for evaluation of BNC210 in a phase 2 social anxiety disorder PREVAIL study

Nov 01, 2021: Bionomics gets FDA approval for trial of social anxiety disorder treatment

Sep 20, 2021: Bionomics prepares BNC210 for start of phase 2 acute treatment of

social anxiety disorder trial

Sep 09, 2021: Alpha Cognition to Webcast Live on ALPHA-1062 at Life Sciences
Investor Forum September 16th

Sep 07, 2021: Alpha Cognition announces the acceptance of its US FDA investigational
new drug application (IND) for lead candidate, ALPHA-1062 for mild to moderate
Alzheimer's Disease

Jul 08, 2021: Novamind selected as research site for Bionomics' PTSD clinical trial
Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 180 Life Sciences Corp, 2022
Pipeline by AlphaCognition Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Bionomics Ltd, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by DanPET AB, 2022
Pipeline by Epigen Biosciences Inc, 2022
Pipeline by Lupin Ltd, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Neuro Bio Ltd, 2022
Pipeline by Serenity Bioworks Inc, 2022
Pipeline by SK Life Science Inc, 2022
Pipeline by Vanda Pharmaceuticals Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Dormant Products, 2022 (Contd..3)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Neuronal Acetylcholine Receptor Subunit Alpha 7 (CHRNA7) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/N3FFA60BCEF0EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N3FFA60BCEF0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

